Metabolic & Cardiometabolic
Does a gut hormone keep blood sugar down after a meal?
The claim, precisely: GLP-1 limits postprandial glucose
Yes — this is well-established core physiology, the same biology behind GLP-1 weight-loss drugs.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
GLP-1 stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and curbs appetite (the 'ileal brake') — the canonical physiology explaining why slowing nutrient delivery (lente carb, viscous fiber, RS) blunts glucose, and the backbone of the GLP-1-agonist drug class.
The evidence (4)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Thazhath 2016 2016 · Diabetes | RCT | supports | high | [FT-verified] exenatide slows small-intestinal transit lowers postprandial glucose |
| Holst JJ 2007 · Physiol Rev | mechanism | supports | high | Authoritative GLP-1 physiology: incretin + ileal brake + DPP-4 inactivation |
| Holst JJ 2007 · Physiol Rev | mechanism | supports | high | canonical GLP-1 stimulates insulin inhibits glucagon limiting postprandial excursions; ileal brake |
| Rayner 2020 2020 · Diabetes Care | RCT | supports | high | [FT-verified] sustained lixisenatide maintains gastric-emptying slowing + reduced postprandial glycemia ⚠️ correction-on-file (Crossref) - kept, corrigendum not retraction |
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.